Frequently asked questions (FAQs)


TASCENSO ODT contains the same proven fingolimod that you might be familiar with, but it comes in an orally disintegrating tablet (ODT) formulation.1

TASCENSO ODT’s unique formulation can be taken with or without water and dissolves in seconds.

The tablet is taken once daily, with or without food.1

The FDA found TASCENSO ODT to have the same safety, same efficacy and the same side effects as Gilenya® (fingolimod) capsules.2  The difference is that it comes in a unique easy-to-swallow, orally disintegrating tablet formulation, which might be a convenient option for you.2

TASCENSO ODT is bioequivalent to Gilenya® (fingolimod) capsules, but it comes in a unique orally disintegrating tablet formulation.2 Because TASCENSO ODT has a unique formulation it is not a generic product and cannot be substituted by Gilenya or generic fingolimod at the pharmacy level.3

Find out more

Fingolimod blocks lymphocytes from leaving the lymph node, reducing the number of lymphocytes in the blood.1

It is thought this may reduce lymphocyte migration into the central nervous system.

Find out more

Download the enrolment form below and share it with your healthcare provider to discuss why you think TASCENSO ODT may be suited to your needs.

Download form

With TASCENSO ODT, no special storage conditions are required, the product should be stored at room temperature (68°F to 77°F) and protected from moisture.1

Take the TASCENSO ODT immediately after opening the blister pack and do not store it outside the blister pack for future use.

Read more

TASCENSO ODT may harm your unborn baby. 1 If you are thinking about becoming pregnant or if you get pregnant, tell your healthcare provider right away.

Yes. A very small amount of product residue may remain inside the pack and the ODT may appear to have a feathered edge. This is normal and you will still receive the correct dose.

Use dry hands when opening the blister pack and peel back the foil covering of 1 blister pack. Gently remove the orally disintegrating tablet (ODT). Do not push the ODT through the foil.

As soon as the blister pack is opened, remove the ODT and place it on your tongue, allowing it to dissolve. Do not store the TASCENSO ODT outside the blister pack for future use.

Read more

Finance and Insurance

If you are eligible, Cycle Vita will provide you with temporary free goods while your insurance coverage is being determined, through the Bridge Program.*

Through Cycle Vita, our dedicated in-house patient support hub, eligible* patients prescribed TASCENSO ODT will have access to the Bridge Program. The Bridge Program is available if you have an urgent medical need for TASCENSO ODT, such as:

  • If you are switching to TASCENSO ODT from another fingolimod treatment while Cycle Vita secures appropriate benefit verification and authorization
  • If you are an existing patient and are experiencing a temporary disruption in TASCENSO ODT therapy due to changes in your insurance coverage

If you are a commercially insured eligible patient who has been prescribed TASCENSO ODT, you may pay as little as $0 in co-pay*. To find out more about eligibility criteria please contact Cycle Vita on +1 (888) 360-8482.

Getting Started

Eligible* patients who are switching to TASCENSO ODT from another fingolimod treatment will have access to our Bridge Program while Cycle Vita secures appropriate benefit verification and authorization.

No. You should not take TASCENSO ODT and fingolimod capsules at the same time.

Once you start TASCENSO ODT, you should stop taking fingolimod capsules.

Our priority is to ensure you experience a smooth transition to TASCENSO ODT.

If you are currently taking the same dose (0.25 mg or 0.5 mg) of another fingolimod product (Gilenya® (fingolimod) capsules or generic fingolimod capsules), a FDO will not be required, providing you have not had a lapse in treatment for 14 days or more.1

If you are currently not on another fingolimod treatment or are increasing your fingolimod dose (from 0.25 mg to 0.5 mg), you will need to have baseline assessments and a first dose observation to initiate therapy. 1

Through Cycle Vita, eligible patients will have access to in-home FDO and baseline assessments as necessary to initiate your treatment.

A healthcare provider will be with you for at least 6 hours after taking your first dose of TASCENSO ODT.

Children will also be observed by a healthcare provider for at least 6 hours after taking their first dose of 0.5 mg of TASCENSO ODT when switching from the 0.25 mg dose.

FDOs are available in-home or at a neutral location if necessary, through the TASCENSO Time Program. Alternatively, you or your healthcare provider may prefer for the FDO to be carried out at your hospital. Discuss with your healthcare provider what may be best for you.

Find out more

TASCENSO ODT will be distributed via a limited network of specialty pharmacies focused on MS and patient care, integrated with Cycle Vita, our dedicated in-house patient support hub. As part of the onboarding process you will be introduced to your specialty pharmacy who will send your shipments of TASCENSO ODT.

You should expect to receive calls from the Cycle Vita team and your specialty pharmacy to support you in your treatment. Don’t forget to save their numbers in your phone so you know to answer when they call.

Cycle Vita

The Cycle Vita team are just a phone call away. You can expect to hear from two types of people at Cycle Vita:

  • Access Specialists – help you access TASCENSO ODT through enrollment, financial and pharmacy support*
  • Clinical Specialists – provide clinical education, clinical support and medication administration support*
+1 (888) 360-8482

When you are prescribed TASCENSO ODT you can expect financial, logistics and educational support, including:

  • Bridge Program – If you are taking another fingolimod treatment, a free supply of TASCENSO ODT is available while we secure appropriate benefit verification and prior authorization. It may also be requested if you experience a temporary disruption in therapy due to insurance coverage.
  • Co-pay Program – If you are commercially insured and eligible you may pay as little as $0.
  • Medical Adherence – Registered Clinicians can provide you with training to help you keep on top of your medication schedule

As soon as Cycle Vita receives your completed enrollment form, we can provide individualized support to eligible* patients, such as access to treatment, financial and pharmacy support, as well as clinical education and medication administration support. We will reach out to you and your doctor in order to take the next steps.

Please refer to our Useful Resources page for more information.

Useful Resources

If you have further questions about TASCENSO ODT please reach out to us at where our team would be happy to help.


1. TASCENSO ODT (fingolimod). Prescribing Information. Cycle Pharmaceuticals Ltd.
2. Data on file: REF-00069.
3. FDA., 2022. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Accessed January 3rd 2023. Available:

*Some areas of support may not be accessible to all patients. Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only. For more detailed information about eligibility, terms and conditions, please contact the Cycle Vita team at +1 (888) 360-8482.

TASCENSO ODT® is a registered trademark of Handa Neuroscience, LLC. Cycle Vita™ is a trademark of Cycle Pharmaceuticals Ltd.

Gilenya® is a registered trademarks of Novartis AG.